Sino Biopharmaceutical’s TQB2102 cuts progression or death risk by 71% in Phase III breast cancer trial

By Public Technologies
  • Sino Biopharmaceutical presented Phase III results for breast cancer drug TQB2102 at ESMO in Madrid on October 23, 2026.
  • The HER2 bispecific antibody-drug conjugate delayed disease progression versus chemotherapy in patients with HER2-low recurrent or metastatic breast cancer.
  • TQB2102 improved tumor response, with overall survival showing a favorable trend.
  • Treatment-related lung inflammation was uncommon, with no related deaths; treatment discontinuations due to adverse events were comparable to chemotherapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk